Document is current

Article History

Received: 4 July 2024

Accepted: 4 March 2025

First Online: 28 March 2025

Declarations

:

: The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the local ethics committee of the Ludwig Maximilian University Munich (Date February 17, 2021/No. 20-1122) and Friedrich-Alexander-Universität Erlangen– Nürnberg (Date May 26, 2020/No. 195_20B, Date January 28, 2016 /16-17-Br, Date May 19, 2020 /17-10-B). All centres were acting according to their regulatory requirements. Informed consent was obtained from patients at the LMU University Hospital for participation in this study. At the Uniklinikum Erlangen, patients provided broad consent for the use of their data in research. The use of anonymized data complies with the guidelines and regulations set forth by the Ethics Committee.

: Not Applicable.

: LH declares speakers and advisory board honoraria from: Bristol-Myers Squibb GmbH & Co. KGaA, Immunocore Ireland Ltd, Kyowa Kirin GmbH, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Pieris Pharmaceuticals, Pierre Fabre Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Stemline Therapeutics Switzerland GmbH, SUN Pharmaceutical Europe Industries BV, Therakos (UK) LTD. Patents of LH: IL-12 plasmid DNA; VEGF-D for lymphangiogenesis; soluble prognostic marker for melanoma. LH declares participation in clinical studies within the institution with: Agenus, AstraZeneca Inc., Bristol Myers Squibb, Huya Bioscience, IO Biotech, Merck Sharp & Dohme GmbH, Pfizer, Pierre Fabre, Regeneron, Replimune, Sanofi Aventis. CB declares speaker´s and advisory board honoraria from: Bristol-Myers Squibb, Immunocore Ireland Ltd, InflaRx, MSD, Novartis, Pierre Fabre, Regeneron, and Sanofi-Aventis. CB declares participation in clinical studies within the institution with: BioNTech, Bristol Myers Squibb, Eikon, Erasca, InflaRx, IO Biotech, Iovance, Kartos, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Regeneron, and Sanofi Aventis. LF declares speaker´s and advisory board honoraria from: Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, Abbvie, UCB, Biotest, AC-Immune, Vaderis Therapeutics, InflaRx, Alys Pharmaceuticals. All remaining authors have declared no potential conflicts of interest.